Phathom Pharmaceuticals, Inc. business relationships
Companies named in Phathom Pharmaceuticals, Inc.’s 10-K filed 2026-02-26, and public companies whose annual reports name Phathom Pharmaceuticals, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.7 / 10
- AI naming
- 5 / 100 Top 3% in its category
- Agent readiness
- 25 / 100
- AI adoption
- 0 / 100
Named in Phathom Pharmaceuticals, Inc.’s annual report 4
“In addition, we are required to make milestone and royalty payments to Takeda, from whom we have in-licensed the rights to develop and commercialize vonoprazan in the United States, Europe, and Canada pursuant to the Takeda License, and we have ongoing financial obligations under our Loan Agreement...” SEC filing
“Our patent portfolio covering vonoprazan consists predominantly of patents and patent applications that are exclusively licensed to us from Takeda pursuant to the license agreement we entered into on May 7, 2019, or the Takeda License.” SEC filing
“We plan to rely, in part, on third parties, including Takeda and any future collaborators, vendors or contract research organizations, to comply with these adverse event reporting requirements.” SEC filing
“We rely on the Takeda License to provide us rights to develop and commercialize vonoprazan in the United States, Europe, and Canada.” SEC filing
Companies whose annual reports name Phathom Pharmaceuticals, Inc. 1
“Branded, prepackaged combination products includes Voquezna ® Triple Pak ® (vonoprozan/amoxicillin/clarithromycin) and Voquezna Dual Pak ® manufactured and sold by Phathom Pharmaceuticals.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.